Pédiatrie Tumeurs solides CRISP (IC 2017-08 / ITCC 053) A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies. Paris ISABELLE AERTS
Recherches "plusieurs pathologies" DERMACLIC (IC 2019-12) Study on skin toxicities induced by cancer treatments Paris
Sein métastatique RH+ DOLAF An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib Saint-Cloud
Pédiatrie Tumeurs solides GO40871 A PHASE I/II, MULTICENTER, OPEN-LABEL, MULTI-ARM;STUDY EVALUATING THE SAFETY, TOLERABILITY,;PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF;IDASANUTLIN IN COMBINATION WITH EITHER;CHEMOTHERAPY OR VENETOCLAX IN THE TREATMENT OF;PEDIATRIC AND YOUNG ADULT PATIENTS WITH;RELAPSED/REFRACTORY ACUTE LEUKEMIAS OR SOLID;TUMORS Paris FRANCOIS DOZ
Pédiatrie Tumeurs solides I3Y-MC-JPCS JPCS(2.1) Clinical Protocol Addendum Page 1;LY2835219;1. Protocol Addendum I3Y-MC-JPCS(2.1);A Phase 1b Dose Escalation Study of Abemaciclib in;Combination with Temozolomide and Irinotecan (Part A);and Abemaciclib in Combination with Temozolomide;(Part B) in Pediatric and Young Adult Patients with;Relapsed/Refractory Solid Tumors Paris ISABELLE AERTS
Pédiatrie Tumeurs solides LYNPARZA (D0816C000025) A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety;and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with;Solid Tumours Paris ISABELLE AERTS
Recherches "plusieurs pathologies" MCLA-128-CL01 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion Saint-Cloud
Pédiatrie Tumeurs solides MUCILA Multicenter double blind randomized placebo-controlled trial assessing the efficacy of low-level laser therapy in the prevention of chemotherapy-induced mucositis in children and young adults treated for a tumoral disease. Paris
Sein métastatique RH+ AMBRE OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY, COMPARING;STANDARD CHEMOTHERAPY TO ENDOCRINE THERAPY + ABEMACICLIB;COMBINATION AS INITIAL METASTATIC TREATMENT AMONG PATIENTS WITH;VISCERAL METASTASIS OF ER+ HER2- BREAST CANCER, HIGH BURDEN;DISEASE Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Soins de support LE DECLIC-EPRI (IC 2019-06) DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI. Paris, Saint-Cloud EVELYNE RENAULT TESSIER